Latest Convertible Notes News

Askari Metals has wiped its debt slate clean and is gearing up for an ambitious exploration campaign at its flagship Nejo Gold & Copper Project in Ethiopia and the Uis Tin-Tantalum-Lithium Project in Namibia.

AVA Risk Group has locked in a strategic investment of up to A$12.6 million from US-based Hale Capital, aiming to boost its footprint in the lucrative US critical infrastructure market. The deal includes convertible notes and warrants priced at an 81% premium, alongside a new board appointment.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Enlitic has locked in commitments for an A$8 million convertible note capital raise, with initial funds arriving immediately and the remainder pending shareholder approval. This funding aims to extend the company’s runway as it advances its AI-driven healthcare solutions.

Jayride Group Limited reports a reduced quarterly loss and secures fresh capital, yet faces ongoing uncertainty over its ability to continue as a going concern during its ASX reinstatement process.

JAYRIDE Group has amended its quarterly cash flow report to correct classification errors, while outlining plans for a new SaaS platform rollout and potential capital raising to support operations.

Native Mineral Resources Holdings has locked in a $3 million convertible note raising from Lind Global Fund III LP, with the option to access up to $10 million. The funding aims to bolster working capital and support growth in the Charters Tower region.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

Tartana Minerals has received $1 million from a new investor as part of a $1.275 million placement, setting the stage for debt reduction and upcoming shareholder decisions.